Cargando…

Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis

The liver is the major drug-metabolizing and drug-detoxifying organ. Many drugs can cause liver damage through various mechanisms; however, the liver response to injury includes a relatively narrow spectrum of alterations that, regardless of the cause, are represented by phlogosis, oxidative stress...

Descripción completa

Detalles Bibliográficos
Autores principales: Calistri, Linda, Rastrelli, Vieri, Nardi, Cosimo, Maraghelli, Davide, Vidali, Sofia, Pietragalla, Michele, Colagrande, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678821/
https://www.ncbi.nlm.nih.gov/pubmed/35046618
http://dx.doi.org/10.3748/wjg.v27.i46.7866
_version_ 1784616390088458240
author Calistri, Linda
Rastrelli, Vieri
Nardi, Cosimo
Maraghelli, Davide
Vidali, Sofia
Pietragalla, Michele
Colagrande, Stefano
author_facet Calistri, Linda
Rastrelli, Vieri
Nardi, Cosimo
Maraghelli, Davide
Vidali, Sofia
Pietragalla, Michele
Colagrande, Stefano
author_sort Calistri, Linda
collection PubMed
description The liver is the major drug-metabolizing and drug-detoxifying organ. Many drugs can cause liver damage through various mechanisms; however, the liver response to injury includes a relatively narrow spectrum of alterations that, regardless of the cause, are represented by phlogosis, oxidative stress and necrosis. The combination of these alterations mainly results in three radiological findings: vascular alterations, structural changes and metabolic function reduction. Chemotherapy has changed in recent decades in terms of the drugs, protocols and duration, allowing patients a longer life expectancy. As a consequence, we are currently observing an increase in chemotherapy-associated liver injury patterns once considered unusual. Recognizing this form of damage in an early stage is crucial for reconsidering the therapy regimen and thus avoiding severe complications. In this frontier article, we analyze the role of imaging in detecting some of these pathological patterns, such as pseudocirrhosis, “yellow liver” due to chemotherapy-associated steatosis-steatohepatitis, and “blue liver”, including sinusoidal obstruction syndrome, veno-occlusive disease and peliosis.
format Online
Article
Text
id pubmed-8678821
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-86788212022-01-18 Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis Calistri, Linda Rastrelli, Vieri Nardi, Cosimo Maraghelli, Davide Vidali, Sofia Pietragalla, Michele Colagrande, Stefano World J Gastroenterol Frontier The liver is the major drug-metabolizing and drug-detoxifying organ. Many drugs can cause liver damage through various mechanisms; however, the liver response to injury includes a relatively narrow spectrum of alterations that, regardless of the cause, are represented by phlogosis, oxidative stress and necrosis. The combination of these alterations mainly results in three radiological findings: vascular alterations, structural changes and metabolic function reduction. Chemotherapy has changed in recent decades in terms of the drugs, protocols and duration, allowing patients a longer life expectancy. As a consequence, we are currently observing an increase in chemotherapy-associated liver injury patterns once considered unusual. Recognizing this form of damage in an early stage is crucial for reconsidering the therapy regimen and thus avoiding severe complications. In this frontier article, we analyze the role of imaging in detecting some of these pathological patterns, such as pseudocirrhosis, “yellow liver” due to chemotherapy-associated steatosis-steatohepatitis, and “blue liver”, including sinusoidal obstruction syndrome, veno-occlusive disease and peliosis. Baishideng Publishing Group Inc 2021-12-14 2021-12-14 /pmc/articles/PMC8678821/ /pubmed/35046618 http://dx.doi.org/10.3748/wjg.v27.i46.7866 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Frontier
Calistri, Linda
Rastrelli, Vieri
Nardi, Cosimo
Maraghelli, Davide
Vidali, Sofia
Pietragalla, Michele
Colagrande, Stefano
Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis
title Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis
title_full Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis
title_fullStr Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis
title_full_unstemmed Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis
title_short Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis
title_sort imaging of the chemotherapy-induced hepatic damage: yellow liver, blue liver, and pseudocirrhosis
topic Frontier
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678821/
https://www.ncbi.nlm.nih.gov/pubmed/35046618
http://dx.doi.org/10.3748/wjg.v27.i46.7866
work_keys_str_mv AT calistrilinda imagingofthechemotherapyinducedhepaticdamageyellowliverblueliverandpseudocirrhosis
AT rastrellivieri imagingofthechemotherapyinducedhepaticdamageyellowliverblueliverandpseudocirrhosis
AT nardicosimo imagingofthechemotherapyinducedhepaticdamageyellowliverblueliverandpseudocirrhosis
AT maraghellidavide imagingofthechemotherapyinducedhepaticdamageyellowliverblueliverandpseudocirrhosis
AT vidalisofia imagingofthechemotherapyinducedhepaticdamageyellowliverblueliverandpseudocirrhosis
AT pietragallamichele imagingofthechemotherapyinducedhepaticdamageyellowliverblueliverandpseudocirrhosis
AT colagrandestefano imagingofthechemotherapyinducedhepaticdamageyellowliverblueliverandpseudocirrhosis